Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: INT070
MIFTS: 59

Intestinal Obstruction

Categories: Fetal diseases, Gastrointestinal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Intestinal Obstruction

About this section

MalaCards integrated aliases for Intestinal Obstruction:

Name: Intestinal Obstruction 12 29 54 6 42 43 15 71

Classifications:

MalaCards categories:
Global: Fetal diseases Rare diseases Metabolic diseases Genetic diseases
Anatomical: Gastrointestinal diseases Neuronal diseases Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8437
ICD9CM 34 560.9
MeSH 43 D007415
NCIt 49 C9175
SNOMED-CT 67 81060008
UMLS 71 C0021843
Sources

Summaries for Intestinal Obstruction

About this section
MedlinePlus : 42 An intestinal obstruction occurs when food or stool cannot move through the intestines. The obstruction can be complete or partial. There are many causes. The most common are adhesions, hernias, cancers, and certain medicines. Symptoms include Severe abdominal pain or cramping Vomiting Bloating Loud bowel sounds Swelling of the abdomen Inability to pass gas Constipation A complete intestinal obstruction is a medical emergency. It often requires surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Intestinal Obstruction is related to hypoganglionosis and hirschsprung disease 1, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Intestinal Obstruction is GDNF (Glial Cell Derived Neurotrophic Factor), and among its related pathways/superpathways is Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Somatostatin and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include colon, small intestine and liver, and related phenotypes are behavior/neurological and cellular

Sources

Related Diseases for Intestinal Obstruction

About this section

Diseases in the Intestinal Obstruction family:

Intestinal Pseudo-Obstruction

Diseases related to Intestinal Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 741)
# Related Disease Score Top Affiliating Genes
1 hypoganglionosis 33.2 RET GDNF ACHE
2 hirschsprung disease 1 33.0 RET NRTN GDNF EDNRB EDN3 ACHE
3 ileus 32.7 GUCY2C CRP CFTR
4 intestinal pseudo-obstruction 32.7 SGO1 RET FLNA EDNRB EDN3 CFTR
5 intestinal volvulus 32.6 GUCY2C CRP ALB
6 intussusception 32.4 CRP CFTR ALB
7 constipation 31.5 RET NRTN GDNF FLNA EDNRB EDN3
8 diarrhea 30.9 GUCY2C FLNA CFTR ALB
9 pseudomyxoma peritonei 30.9 KRT7 KRT20 CDX2
10 intestinal perforation 30.9 NOD2 KRT7 CRP ALB
11 teratoma 30.8 KRT7 KRT20 GATA4 CDX2
12 intestinal tuberculosis 30.8 NOD2 CRP ALB
13 megacolon 30.8 RET NRTN GDNF EDNRB EDN3 ACHE
14 typhoid fever 30.7 CRP CFTR ALB
15 cystic teratoma 30.6 KRT7 KRT20 CDX2
16 hemorrhoid 30.5 FLNA CRP ALB
17 bacterial infectious disease 30.5 NOD2 CRP CFTR CD8A
18 tuberculous peritonitis 30.4 CRP ALB
19 celiac disease 1 30.4 NOD2 CRP CD8A ALB
20 respiratory failure 30.4 GATA4 CRP CFTR ALB ACHE
21 portal hypertension 30.4 EDNRB CFTR ALB
22 cholangiocarcinoma 30.4 MTOR KRT7 KRT20 CDX2
23 signet ring cell adenocarcinoma 30.4 KRT7 KRT20 CDX2
24 jejunal adenocarcinoma 30.4 KRT7 KRT20 CDX2
25 appendix adenocarcinoma 30.4 KRT7 KRT20 CDX2
26 mucinous adenocarcinoma 30.4 KRT7 KRT20 CDX2
27 intrahepatic cholangiocarcinoma 30.4 KRT7 KRT20 CDX2 ALB
28 hydronephrosis 30.4 GATA4 FLNA CRP ALB
29 horseshoe kidney 30.4 KRT7 KRT20 CDX2
30 taeniasis 30.3 FLNA CD8A ALB
31 ovarian germ cell teratoma 30.3 RET KRT7
32 ovarian brenner tumor 30.3 KRT7 KRT20
33 duodenitis 30.2 CRP CD8A ALB
34 abdominal tuberculosis 30.2 NOD2 CRP ALB
35 pneumocystosis 30.2 CRP CD8A ALB
36 splenic disease 30.2 CRP CD8A ALB
37 syphilis 30.2 CRP CD8A ALB
38 neuroendocrine tumor 30.2 RET MTOR KRT20 CDX2
39 vesicoureteral reflux 1 30.2 RET GDNF CRP ALB
40 kidney disease 30.2 RET MTOR EDNRB CRP CFTR ALB
41 patent ductus arteriosus 1 30.1 GATA4 FLNA CRP ALB
42 polyneuropathy 30.1 GDNF CRP ALB ACHE
43 cystic kidney disease 30.1 MTOR EDNRB CFTR ALB
44 cystitis 30.1 KRT7 KRT20 GDNF CRP CDX2
45 cholangitis 30.0 NOD2 CRP CFTR ALB
46 lung disease 30.0 RET FLNA CRP CFTR CD8A ALB
47 lung cancer susceptibility 3 30.0 RET MTOR KRT7 KRT20 CDX2 CD8A
48 autosomal dominant polycystic kidney disease 30.0 MTOR EDNRB CFTR ALB
49 exanthem 30.0 RET MTOR CRP CD8A ALB
50 mesenteric lymphadenitis 29.9 CRP CD8A

Comorbidity relations with Intestinal Obstruction via Phenotypic Disease Network (PDN): (show top 50) (show all 56)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Anxiety
Ascending Colon Cancer Bronchitis
Candidiasis Cecal Benign Neoplasm
Cervical Cancer Chronic Intestinal Vascular Insufficiency
Chylomicron Retention Disease Colorectal Cancer
Crohn's Disease Decubitus Ulcer
Deficiency Anemia Descending Colon Cancer
Enterovesical Fistula Esophageal Disease
Esophagitis Familial Atrial Fibrillation
Gastric Cancer Gastrointestinal System Cancer
Generalized Atherosclerosis Heart Disease
Hepatic Flexure Cancer Hydronephrosis
Hypertension, Essential Hypothyroidism
Inflammatory Bowel Disease 1 Intestinal Disease
Intestinal Perforation Intestinal Volvulus
Iron Deficiency Anemia Irritable Bowel Syndrome
Jejunal Cancer Kidney Disease
Marasmus Neutropenia
Osteoporosis Ovarian Cancer
Pancreatic Cancer Pancreatitis, Hereditary
Paralytic Ileus Peritonitis
Postgastrectomy Syndrome Protein-Energy Malnutrition
Radiation Cystitis Rectosigmoid Junction Neoplasm

Graphical network of the top 20 diseases related to Intestinal Obstruction:



Diseases related to Intestinal Obstruction
Sources

Symptoms & Phenotypes for Intestinal Obstruction

About this section

UMLS symptoms related to Intestinal Obstruction:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Intestinal Obstruction:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.26 ACHE CFTR EDN3 EDNRB FLNA GDNF
2 cellular MP:0005384 10.25 ALB CD8A CDX2 EDNRB FLNA GATA4
3 digestive/alimentary MP:0005381 10.22 ALB CDX2 CFTR EDN3 EDNRB FLNA
4 cardiovascular system MP:0005385 10.16 ALB CDX2 CRP EDNRB FLNA GATA4
5 homeostasis/metabolism MP:0005376 10.13 ACHE ALB CDX2 CFTR CRP EDNRB
6 endocrine/exocrine gland MP:0005379 10.11 ALB CD8A CDX2 CFTR EDNRB GATA4
7 growth/size/body region MP:0005378 10.1 ACHE CDX2 CFTR EDNRB FLNA GATA4
8 immune system MP:0005387 9.93 ALB CD8A CFTR CRP EDNRB FLNA
9 mortality/aging MP:0010768 9.86 ACHE ALB CD8A CDX2 CFTR EDN3
10 muscle MP:0005369 9.23 ACHE ALB EDNRB GATA4 GDNF MTOR
Sources

Drugs & Therapeutics for Intestinal Obstruction

About this section

Drugs for Intestinal Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
2
tannic acid Approved Phase 4 1401-55-4
3
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
4
Bisacodyl Approved Phase 4 603-50-9
5
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
8
Phentermine Approved, Illicit Phase 4 122-09-8 4771
9
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
10
Empagliflozin Approved Phase 4 864070-44-0
11
Linagliptin Approved Phase 4 668270-12-0 10096344
12
Canagliflozin Approved Phase 4 842133-18-0
13
Liraglutide Approved Phase 4 204656-20-2 44147092
14
Morphine Approved, Investigational Phase 4 57-27-2 5288826
15
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
16
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
17
Cimetropium Experimental, Investigational Phase 4 150521-16-7
18 Parasympatholytics Phase 4
19 Cholinergic Antagonists Phase 4
20 Hormone Antagonists Phase 4
21 Hormones Phase 4
22 Cola Phase 4
23 Nutrients Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Anti-Bacterial Agents Phase 4
26 Anti-Infective Agents Phase 4
27 Neuromuscular Agents Phase 4
28 Neuromuscular Nondepolarizing Agents Phase 4
29 Antitubercular Agents Phase 4
30 beta-Lactamase Inhibitors Phase 4
31 Adrenergic Agents Phase 4
32 Liver Extracts Phase 4
33 Sympathomimetics Phase 4
34 Anti-Obesity Agents Phase 4
35 Appetite Depressants Phase 4
36 Sodium-Glucose Transporter 2 Inhibitors Phase 4
37 Incretins Phase 4
38 Dipeptidyl-Peptidase IV Inhibitors Phase 4
39 Sitagliptin Phosphate Phase 4
40 Hypoglycemic Agents Phase 4
41 Lipid Regulating Agents Phase 4
42 Anti-Inflammatory Agents Phase 4
43 Narcotics Phase 4
44 Analgesics, Opioid Phase 4
45 Anesthetics Phase 4
46 Central Nervous System Depressants Phase 4
47 Analgesics Phase 4
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4
49 Anesthetics, Local Phase 4
50
Allantoin Approved Phase 3 97-59-6 204

Interventional clinical trials:

(show top 50) (show all 145)
# Name Status NCT ID Phase Drugs
1 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
2 Phase 4 Evaluation of SurgiWrapTM to Minimize Soft Tissue Attachment & Reduce the Incidence of Early Post-Operative Bowel Obstruction in Colorectal Surgery Completed NCT00531739 Phase 4
3 Gastrografin Use in Small Bowel Obstruction Caused by Adherences Completed NCT00601809 Phase 4 Gastrografin®: G
4 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Completed NCT01507246 Phase 4 IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
5 Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction Completed NCT00389116 Phase 4 gastrograffin;water
6 High-volume Polyethylene Glycol Solution (PEG) Versus Low-volume PEG Plus Stimulant Laxative Versus Sennosides for Colon Cleansing Before Colonoscopy: a Randomized, Single Blinded Study Completed NCT01531140 Phase 4 polyethylene glycol +Bisacodyl;Polyethylene glycol;Sennosides
7 Prospective, Multi-centers, Investigator Sponsored, Randomized Controlled Trial Towards Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction Completed NCT01082627 Phase 4 Somatostatin
8 Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery Completed NCT02812186 Phase 4 Rocuronium
9 A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding Completed NCT01654770 Phase 4
10 Non Operative Treatment for Acute Appendicitis: Study on Efficacy and Safety of Antibiotic Treatment (Amoxicillin and Clavulanic Acid) in Patients With Right Sided Lower Abdominal Pain Completed NCT01096927 Phase 4 Amoxicillin and Clavulanic Acid
11 Cost- Effectiveness and Cost-utility of Laparoscopic Versus Open Repair of Ventral Hernia: Randomized Clinical Trial Completed NCT01778387 Phase 4
12 A Simple Oral Nutrition Protocol Reduces Length of Stay in Patients With Regular Radical Cystectomy Completed NCT01777126 Phase 4
13 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Recruiting NCT03849729 Phase 4 Phentermine
14 Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment Recruiting NCT02041234 Phase 4 Incretin analogues;Xenical;SGLT2 inhibitors;DPP-4 Inhibitors
15 The Use of Gastrografin to Help Alleviate Bowel Obstruction Related to Poor Bowel Motility in Gastroschisis Patients. Recruiting NCT03334578 Phase 4 Gastrografin
16 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Terminated NCT01507233 Phase 4 IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
17 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Terminated NCT01507220 Phase 4 morphine sulfate;bupivacaine liposome extended-release injectable suspension
18 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy) Terminated NCT02058290 Phase 4 IV morphine sulfate or Sponsor-approved equivalent;EXPAREL
19 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
20 Prospective Multicenter Trial for Anti-adhesion Effect of GUARDIX-SGⓇ Following Radical Gastrectomy in Patients With Gastric Cancer. Unknown status NCT02198898 Phase 3
21 Bariatric Arterial Embolization for Morbid Obesity Unknown status NCT02786108 Phase 3
22 A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase IIB Study of Oral Naloxone for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-malignant Pain or Malignant Pain Unknown status NCT00020605 Phase 3 naloxone hydrochloride
23 Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers: A Randomised Trial Unknown status NCT00164879 Phase 3
24 A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI) in Subjects Undergoing Abdominal Operation Unknown status NCT01863407 Phase 3 DAM;Normal Saline
25 Phase III, Multicentre, Randomised, Double-blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients. Completed NCT00216372 Phase 3 Lanreotide (microparticle formulation)
26 Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting Completed NCT01834430 Phase 3
27 Endoscopic Stenting and Elective Surgery Versus Emergency Surgery for Left-sided Malignant Colonic Obstruction: A Prospective Randomized Trial. Completed NCT00758186 Phase 3
28 Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. A Randomized Clinical Trial Completed NCT00529412 Phase 3
29 Randomized Phase III Study of 5-FU Continuous Infusion (5FUci) Versus MTX+5-FU Sequential Therapy (MF) in Gastric Cancer With Peritoneal Metastasis (JCOG0106-MF, MF/5FU) Completed NCT00149201 Phase 3 5-FU continuous infusion;MTX + 5-FU sequential therapy
30 Outcome of Palliative Management of Malignant Large Bowel Obstruction With Colorectal Stents or Surgery Completed NCT00140868 Phase 3
31 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00327444 Phase 2, Phase 3 aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
32 Effects of the Abbreviation of Preoperative Fasting With Carbohydrates and Hydrolized Proteins on the Inflammatory Response and Insulin Resistance After Major Abdominal Operations Completed NCT01563965 Phase 3
33 Phase 3 Study of Antibiotic Prophylaxis Use Prior Emergent Surgery, Because of Acute Appendicitis Completed NCT01524081 Phase 3 Metronidazole, Cefuroxime;Amoxicillin (+ clavulanic acid) and Fluconazole;Placebo;Placebo
34 The Therapeutic Role of Gastrografin for Treating Small Bowel Obstruction in Children: A Multi-Centre Canadian Prospective Study Recruiting NCT03573921 Phase 2, Phase 3 Gastrografin
35 A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in the Prevention of Acute Enteritis in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy Withdrawn NCT01473290 Phase 3
36 Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation: A Double-blinded Randomized Controlled Trial Unknown status NCT02784093 Phase 2 Gastrografin
37 Prospective, Randomized Trial Comparing Early Laparoscopic Enterolysis Versus a Time-limited Trial of Nonoperative Management for High-grade Small Bowel Obstruction Unknown status NCT02692638 Phase 2
38 An International, Multicentric, Prospective, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 MG Associated to Standard of Care in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction Completed NCT02275338 Phase 2 Lanreotide Autogel
39 Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients Completed NCT01076803 Phase 2 Lanreotide (acetate)
40 Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis Completed NCT00332696 Phase 2 Octreotide LAR;Octreotide (Immediate release);methylprednisolone;Placebo
41 The Efficacy and Safety of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Adhesions After Laparoscopic Gynecological Surgery: a Randomized Controlled Trial Completed NCT02166554 Phase 1, Phase 2
42 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
43 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
44 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
45 A Controlled Randomized Multicenter Study to Assess the Safety and Performance of Adhibit™ Adhesion Prevention Gel in Myomectomy Surgery Completed NCT00562471 Phase 1, Phase 2
46 A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00396591 Phase 2 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
47 A Multicenter, Open-label, Single-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum- and Erlotinib-resistant Locally Advanced or Metastatic Non-small-cell Lung Adenocarcinoma Completed NCT00284141 Phase 2 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
48 A Multicenter, Randomized, Double-blind, Parallel-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum-resistant and topotecan-and/or Liposomal Doxorubicin-resistant Advanced Ovarian Cancer Completed NCT00327171 Phase 2 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
49 A Pilot Randomised Study to Compare Combination Antibiotic Therapy (Ciprofloxacin, Doxycycline and Hydroxychloroquine) With Standard Therapy (Budesonide) in the Treatment of Active Crohn's Disease Completed NCT01783106 Phase 2 Ciprofloxacin;Doxycycline;Hydroxychloroquine;Budesonide
50 Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center Recruiting NCT04027348 Phase 2 Dexamethasone;Metoclopramide;Octreotide

Search NIH Clinical Center for Intestinal Obstruction

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Heavy mineral oil
Mineral Oil
Mineral Oil, Light
MINERAL OIL,EXTRA HEAVY
MINERAL OIL,MEDIUM
MINERAL OIL,REFINED

Cochrane evidence based reviews: intestinal obstruction

Sources

Genetic Tests for Intestinal Obstruction

About this section

Genetic tests related to Intestinal Obstruction:

# Genetic test Affiliating Genes
1 Intestinal Obstruction 29
Sources

Anatomical Context for Intestinal Obstruction

About this section

MalaCards organs/tissues related to Intestinal Obstruction:

40
Colon, Small Intestine, Liver, Pancreas, Lung, Kidney, Appendix
Sources

Publications for Intestinal Obstruction

About this section

Articles related to Intestinal Obstruction:

(show top 50) (show all 11237)
# Title Authors PMID Year
1
Primary jejunal melanoma as a cause of adult intussusception: a case report and review of literature. 61 42
31692747 2019
2
Abdominal Emergencies in Inflammatory Bowel Disease. 42
31676053 2019
3
Tube feeding associated postoperative intussusceptions: A single center case series study. 42
31689848 2019
4
Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. 54 61
18782827 2008
5
Impact of nutrition on phenotype in CFTR-deficient mice. 61 54
17805210 2007
6
Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. 54 61
17030173 2006
7
Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared with their littermate controls. 61 54
16418321 2006
8
Distal intestinal obstruction syndrome in adults with cystic fibrosis. 61 54
15181619 2004
9
Liver cirrhosis and portal hypertension in cystic fibrosis. 61 54
14501614 2003
10
Gdnf haploinsufficiency causes Hirschsprung-like intestinal obstruction and early-onset lethality in mice. 54 61
11774071 2002
11
Cellular localization of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. 61 54
10959824 2000
12
[Gastrointestinal complications of adult patients with cystic fibrosis]. 61 54
10494610 1999
13
Clinical and genetic risk factors for cystic fibrosis-related liver disease. 54 61
9917439 1999
14
Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. 54 61
8589719 1996
15
Defining the Burden of Emergency General Surgery in Transplant Patients: A Nationwide Examination. 61
31421379 2020
16
Laparoscopic Compared With Open Resection for Colorectal Cancer and Long-term Incidence of Adhesional Intestinal Obstruction and Incisional Hernia: A Systematic Review and Meta-analysis. 61
31804272 2020
17
Strongyloides stercoralis: a rare and severe presentation in a pregnant woman. 61
31814031 2019
18
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. 61
31850931 2019
19
Abdomen cocoon causing chronic abdominal pain and intestinal obstruction; a case series. 61
31692629 2019
20
Partial Malrotation of Bowel Loops in an Adolescent with Left Hypochondrial Pain. 61
31779750 2019
21
Ileo-ileal knot: a rare cause of acute intestinal obstruction. 61
30207038 2019
22
Acute cecal volvulus: A diagnostic and therapeutic challenge in emergency: A case report. 61
31737261 2019
23
A cross sectional study to investigate internal hernia post left-sided colectomy preserving superior rectal artery. 61
31763040 2019
24
Closed loop bowel obstruction secondary to left paraduodenal hernia (of Landzert). 61
31811091 2019
25
End-to-end intestinal anastomosis using a novel biodegradable stent for laparoscopic colonic surgery: a multicenter study. 61
31256255 2019
26
Laparoscopic repair of a right-sided paraduodenal hernia. 61
31844514 2019
27
Comparison of Yang-Monti ileal ureter-bladder anastomosis versus Yang-Monti ileal ureter-ureteral anastomosis for the treatment of ureteral stenosis: a randomized controlled trial in a miniature pig model. 61
31822266 2019
28
Axial torsion of Meckel's diverticulum causing acute peritonitis in the first trimester of pregnancy: a case report. 61
31808013 2019
29
Intestinal perforation in unusual location. 61
31696721 2019
30
Epidermolysis bullosa with pyloric atresia consistently demonstrates concurrent low intra-basal epidermal and lamina lucida cleavage planes: a survey of six cases. 61
31851393 2019
31
Early unplanned reoperations after gastrectomy for gastric cancer are different between laparoscopic surgery and open surgery. 61
30937616 2019
32
15-year experience of laparoscopic gastrectomy in advanced gastric cancer: analysis on short-term and long-term oncologic outcome. 61
31820153 2019
33
Disseminated Gastrointestinal Basidiobolomycosis (GIB) in an infant from Western India. 61
31667059 2019
34
Diagnosis of Hirschsprung Disease. 61
31791203 2019
35
Deep infiltrating endometriosis: An atypical cause of intestinal obstruction. 61
31806253 2019
36
Acupuncture Combined with Early Enteral Nutrition on Patients with Postoperative Laparoscopic Common Bile Duct Exploration: A Prospective Randomized Trial. 61
31848889 2019
37
Self-expanding Metallic Stent Placement in Malignant Terminal Ileal Stricture. 61
31779752 2019
38
[Superior mesenteric artery syndrome in a 12-year-old adolescent. Clinical case]. 61
31758903 2019
39
Laparoscopic versus open appendectomy in pediatric patients with complicated appendicitis: a meta-analysis. 61
30805783 2019
40
Successful orthotopic uterine allotransplantation in a rabbit model using aorta and cava anastomoses: a short-term viability study. 61
31776706 2019
41
[Analysis on operational safety of chronic radiation intestinal injury]. 61
31770834 2019
42
Laparoscopic extralevator abdominoperineal resection versus laparoscopic abdominoperineal resection for lower rectal cancer: A retrospective comparative study from China. 61
31526895 2019
43
Totally extraperitoneal approach to laparoscopic lateral lymph node dissection for patients with recurrent lateral pelvic lymph nodes after rectal cancer surgery: a novel technique-M TEP LLND. 61
30972565 2019
44
Diverting Stoma Versus No Diversion in Laparoscopic Low Anterior Resection: A Single-center Retrospective Study in Japan. 61
31662547 2019
45
In utero ileal volvulus and intestinal perforation associated with enteric duplication cyst presenting with preterm labour and acute abdomen in newborn. 61
31780621 2019
46
Injuries due to foreign body ingestion and insertion in children: 10 years of experience at a single institution. 61
31693772 2019
47
Prospective international multicenter pectopexy trial: Interim results and findings post surgery. 61
31765998 2019
48
Radiographic diagnosis of small intestinal obstruction in pet rabbits (Oryctolagus cuniculus): 63 cases. 61
31515805 2019
49
Pouch of Douglas internal hernia successfully treated laparoscopically. 61
31793455 2019
50
An Unusual Cause of Intestinal Obstruction. 61
31744707 2019
Sources

Variations for Intestinal Obstruction

About this section

ClinVar genetic disease variations for Intestinal Obstruction:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GATA4 NM_002052.5(GATA4):c.94G>C (p.Ala32Pro)SNV Uncertain significance 599008 8:11565915-11565915 8:11708406-11708406
2 ERF NM_006494.4(ERF):c.1636C>T (p.Arg546Ter)SNV Uncertain significance 599007 19:42752628-42752628 19:42248476-42248476
Sources

Expression for Intestinal Obstruction

About this section
Search GEO for disease gene expression data for Intestinal Obstruction.
Sources

Pathways for Intestinal Obstruction

About this section

Pathways related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.05 GATA4 CFTR CDX2 ALB
Sources

GO Terms for Intestinal Obstruction

About this section

Biological processes related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.88 NOD2 GDNF EDNRB EDN3 CDX2
2 nervous system development GO:0007399 9.85 RET NRTN GDNF EDNRB ACHE
3 cellular response to starvation GO:0009267 9.58 MTOR KRT20 ALB
4 positive regulation of cell differentiation GO:0045597 9.54 GDNF EDN3 CDX2
5 intestinal epithelial cell differentiation GO:0060575 9.43 GATA4 CDX2
6 positive regulation of neuron maturation GO:0014042 9.32 RET MTOR
7 vein smooth muscle contraction GO:0014826 9.26 EDNRB EDN3
8 posterior midgut development GO:0007497 9.16 RET EDNRB
9 enteric nervous system development GO:0048484 9.13 RET GDNF EDNRB
10 neural crest cell migration GO:0001755 9.02 RET NRTN GDNF EDNRB EDN3

Molecular functions related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 toxic substance binding GO:0015643 8.62 GUCY2C ALB
Sources

Sources for Intestinal Obstruction

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....